| Literature DB >> 33842524 |
Vlad R Sabou1, Mary F O'Leary1, Ying Liu2, Paula N Brown2, Susan Murch3, Joanna L Bowtell1.
Abstract
Tart cherries (TC) are a rich source of polyphenols that elicit antioxidant and anti-inflammatory effects. As a consequence, the effects of TC derived supplements on markers of human health, exercise performance and sleep have been investigated. Supplementation protocols have been highly variable across studies and the dose of bioactive compounds used has often been poorly characterized. Specific and non-specific analytical methods were employed for measuring the total polyphenol and anthocyanin content in TC supplements. This review critically analyses the supplementation protocols and the analytical methods used for the characterization of TC supplements, culminating in recommendations for good practice in the analysis and reporting of the polyphenol content and profile of TC products. A literature search was conducted using PubMed/Medline and Web of Science up to May 4th, 2020, including studies published in all years prior. Only articles written in English that provided a TC dietary supplement as opposed to fresh whole TC were included in this review. Forty-three studies were identified as eligible and included for analysis in this review. The studies investigated the effects of TC supplementation on various aspects of human health, exercise recovery and performance and sleep. Twenty studies conducted an analysis of TC supplement and reported total polyphenol/anthocyanin content. Six studies did not report the polyphenol content of the TC supplement used. Seventeen studies reported the TC supplement polyphenol content but this was derived from previously published studies and presumably different supplement batches. The duration of the supplementation protocol ranged from acute supplementation to 84 days, meanwhile the total polyphenol and anthocyanin dose ranged from 143 to 2,140 mg/day and 15 to 547 mg/day, respectively. Due to the variety of specific and non-specific analytical methods used, the relative efficacy of different doses and polyphenol blends cannot reliably be extrapolated from critical analysis of the literature. Future studies should conduct an analysis of the study supplement batch. In addition to analysis and reporting of total polyphenol content, specific analytical methods such as HPLC UV/MS should be used to quantify total and individual anthocyanin contents.Entities:
Keywords: anthocyanins; dietary supplement; exercise recovery; sleep; tart cherry
Year: 2021 PMID: 33842524 PMCID: PMC8032894 DOI: 10.3389/fnut.2021.652094
Source DB: PubMed Journal: Front Nutr ISSN: 2296-861X
Comparison of major nutrients, vitamins and phenolic compounds between tart cherries and other common berries.
| Energy | kcal | 32 | 57 | 52 | 46 | 63 | 50 |
| Water | g | 91 | 84 | 86 | 87 | 82 | 86 |
| Protein | g | 0.67 | 0.74 | 1.20 | 0.46 | 1.06 | 1.00 |
| Total lipid (fat) | g | 0.30 | 0.33 | 0.65 | 0.13 | 0.20 | 0.30 |
| Carbohydrate | g | 7.7 | 14.5 | 11.9 | 12.0 | 16.0 | 12.2 |
| Fiber, total dietary | g | 2.00 | 2.40 | 6.50 | 3.60 | 2.10 | 1.60 |
| Sugars | g | 4.89 | 9.96 | 4.42 | 4.27 | 12.82 | 8.49 |
| Fatty acids, total saturated | g | 0.02 | 0.03 | 0.02 | 0.01 | 0.04 | 0.07 |
| Potassium, K | mg | 153 | 77 | 151 | 80 | 222 | 173 |
| Vitamin C, total ascorbic acid | mg | 59 | 10 | 26 | 14 | 7 | 10 |
| Thiamin, B1 | mg | 0.02 | 0.04 | 0.03 | 0.01 | 0.03 | 0.03 |
| Riboflavin, B2 | mg | 0.02 | 0.04 | 0.04 | 0.02 | 0.03 | 0.04 |
| Niacin, B3 | mg | 0.39 | 0.42 | 0.60 | 0.10 | 0.15 | 0.40 |
| Pantothenic acid, B5 | mg | 0.13 | 0.12 | 0.33 | 0.30 | 0.20 | 0.14 |
| Vitamin B-6 | mg | 0.05 | 0.05 | 0.06 | 0.06 | 0.05 | 0.04 |
| Folate | μg | 24.0 | 6.0 | 21.0 | 1.0 | 4.0 | 8.0 |
| Choline | mg | 5.7 | 6.0 | 12.3 | 5.5 | 6.1 | 6.1 |
| Vitamin A, RAE | μg | 1 | 3 | 2 | 3 | 3 | 64 |
| Carotene, beta | μg | 7 | 32 | 12 | 38 | 38 | 770 |
| Vitamin A | IU | 12.0 | 54.0 | 33.0 | 63.0 | 64.0 | 1283.0 |
| Lutein + zeaxanthin | μg | 26.0 | 80.0 | 136.0 | 91.0 | 85.0 | 85.0 |
| Vitamin E (alpha-tocopherol) | mg | 0.29 | 0.57 | 0.87 | 1.32 | 0.07 | 0.07 |
| Vitamin K (phylloquinone) | μg | 2.2 | 19.3 | 7.8 | 5.0 | 2.1 | 2.1 |
| Anthocyanidins, cyanidin | mg | 1.68 | 8.46 | 45.77 | 46.43 | 30.21 | 32.57 |
| Anthocyanidins, peonidin | mg | 24.85 | 29.29 | 0.12 | 49.16 | 1.50 | 0.87 |
| Flavan-3-ols, (-)-epicatechin | mg | 0.42 | 0.62 | 3.52 | 4.37 | 5.00 | 3.83 |
| Flavan-3-ols, (+)-catechin | mg | 3.11 | 5.29 | 1.31 | 0.39 | 4.36 | 0.30 |
| Flavonols, isorhametin | mg | 0.00 | - | 0.00 | - | 0.05 | 0.72 |
| Flavonols, kaempferol | mg | 0.50 | 1.66 | 0.06 | 0.12 | 0.24 | 0.24 |
| Flavonols, myricetin | mg | 0.04 | 1.30 | 0.00 | 6.63 | 0.05 | 0.00 |
| Flavonols, quercetin | mg | 1.11 | 7.67 | 1.05 | 14.84 | 2.29 | 1.47 |
(,
(.
Table presenting the extracted data from the tart cherry supplementation studies included in this review that conducted direct analysis on the dietary supplement used in the supplementation protocol.
| Traustadóttir et al. ( | Oxidative Stress | Tart cherry juice blend (Cherry Pharm) | 236 mL | 2 | 14 | Not applicable | 1,100 | Spectrophotometric analysis with Folin-Ciocalteu's reagent (no reference) | 119 | HPLC (no reference) | Improved markers of anti-oxidant response and reduced markers of oxidative damage |
| Schumacher et al. ( | Knee Osteoarthritis | Tart cherry juice(Cherry Pharm) | 236 mL | 2 | 42 | Not applicable | 900 | Modified Folin-Ciocalteu colorimetric method ( | 60 | pH differential method ( | No difference in symptoms relief compared to placebo |
| Keane et al. ( | Vascular function | Tart cherry concentrate (CherryActive) | 60 mL | 1 | 1 | Not applicable | 178 | Modified Folin-Ciocalteu colorimetric method ( | 73.5 | pH differential method ( | Reduced systolic blood pressure |
| Keane et al. ( | Phytochemical uptake following human consumption | Tart cherry concentrate (CherryActive) | 30 and 60 mL | 1 | 1 | Not applicable | 142.7 | Modified Folin-Ciocalteu colorimetric method ( | 62.47 | pH differential method ( | Increased plasma phenolic levels following both conditions |
| Keane et al. ( | Cognitive performance and vascular function | Tart cherry concentrate (CherryActive) | 60 mL | 1 | 1 | Not applicable | 160.75 | Modified Folin-Ciocalteu colorimetric method ( | 68 | pH differential method ( | Modulated vascular function but no effect on cognitive performance |
| Jackman et al. ( | Muscle protein synthesis | Tart cherry concentrate (CherryActive) | 30 mL | 2 | 14 | Not applicable | Not provided | Not provided | 540 | HPLC ( | No enhancement in muscle protein synthesis |
| Mayta-Apaza et al. ( | Human gut microbiota | Tart cherry juice | 237 mL | 1 | 5 | Not applicable | Not provided | Not provided | 14.9 | HPLC-DAD- ESI-Q/TOFMS ( | Modulated gut microbiota |
| Martin et al. ( | Systemic Inflammation | Tart cherry juice(R.W. Knudsen) | 240 mL | 1 | 28 | Not applicable | 1,827 | Folin–Ciocalteu method ( | Not measured, only indicated authenticity of phenolic profile | HPLC ( | Reduced systemic markers of inflammation |
| Chai et al. ( | Systolic blood pressure and low-density lipoprotein cholesterol | Tart cherry juice (King Orchards) | 240 mL | 2 | 84 | Not applicable | 450 | Not provided | Not measured | Not applicable | Lowered blood pressure and LDL cholesterol |
| Martin and Coles ( | Serum Urate | Tart cherry juice(Coloma Frozen Foods) | 240 mL | 1 | 28 | Not applicable | 993.6 | Modified Folin-Ciocalteu colorimetric method ( | 15.6 | Method not provided | Reduced serum urate |
| Lear et al. ( | Gut microbiome | Tart cherry Concentrate | 30 mL | 2 | 28 | Not applicable | 1,040 | Methods not provided | 296 | Method not provided | No change in gut microbiome, markers of inflammation or indices of glucose tolerance |
| Aboo Bakkar et al. ( | Vascular function | Tart cherry powder (CherryActive) | 1,700 mg | 1 | 28 | Not applicable | 456 | Method not reported | 226 | Method not reported | Attenuated vascular disfunction induced by prolonged forearm occlusion |
| Johnson et al. ( | Cardiometabolic biomarkers in adults with metabolic syndrome | Tart cherry juice (Indian Summers) | 240 mL | 2 | 84 | Not applicable | 2,140 | LC-MS (Reference not provided) | 166 | LC-MS | Reduced LDL cholesterol and vascular cell adhesion molecule-1. No effect on other biomarkers |
| Connolly et al. ( | Recovery from eccentric contractions of the elbow flexors | Tart cherry juice(Cherry Pharm) | 236 mL | 2 | 8 | 4 | 1,200 | Modified Folin-Ciocalteu colorimetric method ( | 80 | pH differential method ( | Improved exercise recovery |
| Bowtell et al. ( | Recovery from single-leg knee extensions | Tart cherry concentrate (CherryActive) | 30 mL | 2 | 10 | 7 | Not provided | Method not provided | 547 | HPLC ( | Improved exercise recovery |
| Levers et al. ( | Recovery from lower body strength exercise | Tart cherry powder (CherryPURE) | 480 mg | 1 | 10 | 7 | 990 | Method not provided | 66 | Method not provided | No improvement in muscle function recovery |
| Beals et al. ( | Recovery from isokinetic concentric/eccentric contractions of the quadriceps | Tart cherry powder (TatVitaCherry) | 30 mg | 2 | 12 | 4 | 733 | Method not provided | 64 | Method not provided | No improvement in muscle strength recovery and other DOMS symptoms |
| Lamb et al. ( | Recovery from eccentric elbow contractions | Tart cherry concentrate (CherryActive) | 30 mL | 2 | 9 | 4 | 589 | Modified Folin-Ciocalteu colorimetric method ( | 15.4 | pH differential method ( | No improvement in muscle function recovery |
| Morgan et al. ( | 15 km time-trial performance | Tart cherry capsules (CherryActive) | 3 capsules | 2 | 7 | 7 | 462.8 | Folin-Denis method (no reference provided) | 256.8 | HPLC (no reference provided) | Improved cycling performance |
| Losso et al. ( | Treatment of insomnia | Tart cherry juice (Indian Summer) | 240 | 2 | 14 | Not applicable | No result provided | No analysis conducted | 287 | HPLC ( | Increased sleep time and sleep efficiency |
Figure 1Diagram illustrating the literature search. The number in brackets indicates the total number of studies identified.
Table presenting the extracted data from the tart cherry supplementation studies included in this review that reported the characterization (polyphenol and anthocyanin content) from previously published studies.
| Bell et al. ( | Uric acid concentration | Tart cherry concentrate (CherryActive) | 30 mL | 1 or 2 | 2 | Not applicable | Not measured | 547 | Bowtell et al. ( | Decrease in serum urate and increase in urinary urate excretion |
| Lynn et al. ( | Arterial Stiffness and Inflammation | Tart cherry concentrate (CherryActive) | 30 mL | 1 | 42 | Not applicable | Not measure | 547 | Bowtell et al. ( | No improvement in arterial stiffness or markers of inflammation |
| Desai et al. ( | Fat oxidation during exercise and cardio-metabolic markers | Tart cherry concentrate (CherryActive) | 30 mL | 2 | 20 | Not applicable | Not measured | 547 | Bowtell et al. ( | No effect of fat utilization during exercise or cardio-metabolic markers |
| Chai et al. ( | Biomarkers of Inflammation and Oxidatve Stress | Tart cherry juice (King Orchards) | 240 mL | 2 | 84 | Not applicable | 450.6 | Not measured | Chai et al. ( | Reduced markers of inflammation and oxidative stress |
| Chai et al. ( | Cognitive performance | Tart cherry juice (King Orchards) | 240 mL | 2 | 84 | Not applicable | 450.6 | Not measured | Chai et al. ( | Improved aspects of cognitive performance |
| Desai et al. ( | Cardio-metabolic markers | Tart cherry concentrate and tart cherry capsules (CherryActive) | 30 mL 4,350 mg | 1 | 1 | Not applicable | Not measured | 270 | Bowtell et al. ( | Reduced insulin concentration and systolic blood pressure |
| Kuehl et al. ( | Muscle pain following long-distance running | Tart cherry juice blend (CherryInc) | 350 mL | 2 | 8 | 7 | 1,200 | 80 | Connolly et al. ( | Reduced subjective muscle pain |
| Howatson et al. ( | Recovery following marathon running | Tart cherry juice (CherryPharm) | 236 mL | 2 | 8 | 5 | 1,200 | 80 | Connolly et al. ( | Improved muscle function recovery |
| Bell et al. ( | Recovery from repeated days of high-intensity stochastic cycling | Tart cherry concentrate (CherryActive) | 30 mL | 2 | 7 | 4 | Not measured | 547 | Bowtell et al. ( | No improvement in subsequent performance. Reduction in systemic markers of oxidative stress and inflammation |
| Bell et al. ( | Recovery from high-intensity cycling | Tart cherry concentrate (CherryActive) | 30 mL | 2 | 8 | 4 | Not measured | 547 | Bowtell et al. ( | Improved muscle function recovery |
| Bell et al. ( | Recovery from intermittent running | Tart cherry concentrate (CherryActive) | 30 mL | 2 | 7 | 4 | 178 | 73.5 | Keane et al. ( | Improved muscle function recovery |
| McCormick et al. ( | Recovery from water polo specific training | Tart cherry concentrate (CherryActive) | 30 mL | 3 | 6 | 6 | Not reported | 810 | Bowtell et al. ( | No improvement in recovery and next day performance |
| Brown et al. ( | Recovery from an intermittent sprinting protocol | Tart cherry concentrate (CherryActive) | 30 mL | 2 | 8 | 4 | 178 | 73.5 | Keane et al. ( | Improved muscle function recovery |
| Morehen et al. ( | Recovery following a professional rugby match | Tart cherry concentrate (CherryActive) | 30 mL | 2 | 7 | 5 | Not reported | 640 | Manufacturer | No improvement in muscle function recovery or markers of inflammation |
| Levers et al. ( | Endurance exercise performance | Tart cherry powder (CherryPURE) | 480 mg | 1 | 10 | 7 | 990 | 66 | Levers et al. ( | Faster half-marathon timing in the tart cherry group |
| Pigeon et al. ( | Sleep duration and quality in subjects suffering of insomnia | Tart cherry juice blend (CherryPharm) | 236 mL | 2 | 14 | Not applicable | 1,100 | 119 | Traustadóttir et al. ( | Decrease in minutes awake after sleeponset |
| Howatson et al. ( | Sleep duration and quality in healthy subjects | Tart cherry concentrate (CherryActive) | 30 mL | 2 | 7 | Not applicable | Not measured | 547 | Bowtell et al. ( | Improvement in sleep duration and quality |
Table presenting the extracted data from the tart cherry supplementation studies included in this review that did not include any characterization of the dietary supplement used.
| Stamp et al. ( | Serum urate and frequency of gout flares | Tart cherry concentrate (Cherryvite) | 7.5, 15, 22.5, 30 mL | 2 | 28 | N/A | No decrease in serum urate or frequency of gout flares |
| Kupusarevic et al. ( | Recovery following a professional rugby union match | Tart cherry gel (Healthspan) | 30 mL | 2 | 5 | 2 | No improvements in muscle soreness or daily well-being scores |
| Abbott et al. ( | Recovery following a professional football match | Tart cherry gel (Healthspan) | 30 mL | 2 | 3 | 0 | No improvement in muscle function recovery |
| Quinlan and Hill ( | Recovery following intermittent running | Tart cherry concentrate (Holland and Barrett) | 30 mL | 2 | 8 | 5 | Improved muscle function recovery |
| Keane et al. ( | Cycling performance | Tart cherry concentrate (CherryActive) | 60 mL | 1 | 1 | 1 | Improved some aspects of cycling performance |
| Davis and Bellar ( | Cycling performance | Tart cherry powder (Anderson Global Group) | 500 mg | 1 | 7 | 7 | No effects on cycling performance or muscle oxygenation |